Japan "Library" Gets Samples From Makers For New Use Studies
This article was originally published in PharmAsia News
Three Japanese drug makers are among 14 pharmaceutical companies that have agreed to supply samples of their medicines to Keio University's "library of drugs.
You may also be interested in...
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.